Company Overview - Recursion (NASDAQ:RXRX) is a clinical stage TechBio company focused on decoding biology to enhance drug discovery processes [3] - The company operates a platform known as Recursion OS, which generates extensive proprietary biological and chemical datasets, utilizing advanced machine-learning algorithms to identify relationships across biology and chemistry [3] - Recursion conducts millions of wet lab experiments weekly and operates one of the most powerful supercomputers globally, integrating technology with biology and chemistry to innovate in medicine [3] Upcoming Financial Updates - Recursion will provide business updates and report its fourth quarter and full year 2024 financial results on February 28, 2025, before the market opens [1] - An earnings call will be held on the same day at 8:30 am ET, with a live stream available on various platforms including X (formerly Twitter), LinkedIn, and YouTube [2] Company Locations - The company is headquartered in Salt Lake City and is a founding member of BioHive, a collective for the Utah life sciences industry [4] - Recursion has additional offices in Toronto, Montréal, New York, London, Oxford area, and the San Francisco Bay area [4]

Core Insights - The Altitude Lab Fund is launched to support early-stage biotechnology startups in Salt Lake City, aiming to provide capital, lab space, and mentorship amidst federal funding disruptions [1][2][3] Industry Overview - Federal grants, amounting to approximately $4.5 billion annually through SBIR and STTR, have been crucial for biotech innovation, but recent policy changes have left around 1,500 health-related startups in a precarious position [2] - Salt Lake City has emerged as a biotechnology hub, with Altitude Lab's startups raising over 50% of early-stage life science capital in Utah, totaling $154 million from 2020 to 2024 [3] Company Initiatives - The fund will provide pre-seed investments ranging from $100,000 to $250,000, along with 12 months of lab and office space, and access to a competitive accelerator program [8] - Altitude Lab aims to foster a diverse generation of founders, particularly supporting female and underrepresented entrepreneurs who currently receive only 15% of SBIR funding and 3% of venture capital [3][5] Leadership and Management - The fund will be led by Chris Gibson, CEO of Recursion, along with David Bearss and Chandana Haque, focusing on supporting biotech innovation and entrepreneurship [4]

Core Insights - Altitude Lab has successfully incubated startups that have raised a total of $154 million in early-stage funding since its inception in 2020 [1] - The inaugural Gibson Founder Fellowship was awarded to Carmen Kivisild, CEO of Elnora AI, providing up to $150,000 in funding and support for early-career scientists [1][2] - Altitude Lab anticipates a significant increase in Series A funding rounds from its alumni and founder community in 2025, following major value inflection points achieved in 2024 [3] Company Overview - Altitude Lab is an accelerator program located in Salt Lake City's BioHive Hub, focused on early-stage life science and healthcare companies [4] - The initiative aims to foster socially-responsible entrepreneurship, job creation, and economic productivity in Utah [4] - Altitude Lab operates under the Recursion Foundation, a nonprofit organization [4] Startup Performance - Currently, 19 startups are in Altitude Lab's cohort, with 12 alumni, and 90% of participating startups have successfully raised capital [6] - Notable achievements include Peel Therapeutics completing a Phase 1 trial and Rebel Medicine receiving IND approval for Alevatrix [6] - 70% of startups are led by at least one underrepresented founder, highlighting diversity within the program [6]

Recursion Pharmaceuticals (RXRX) is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $28.73 billion. The consensus mark for RXRX’s loss per share is pinned at 36 cents.See the Zacks Earnings Calendar to stay ahead of market-making news.In the past 60 days, the Zacks Consensus Estimate for Recursion’s 2024 loss per share has remained constant at $1.57. During the same time frame, the company’s 2025 loss for ...

Core Viewpoint - Recursion Pharmaceuticals' stock surged by 15.8% due to Nvidia's decision to retain its shares in the company, which is seen as a vote of confidence despite Nvidia exiting other AI stocks [1][2][3]. Group 1: Nvidia's Influence - Nvidia disclosed its holdings, revealing it maintained its 7.7 million shares in Recursion Pharmaceuticals while selling off positions in other AI stocks [2]. - The decision by Nvidia to keep its stake in Recursion is interpreted positively by investors, suggesting confidence in Recursion's potential [3][4]. Group 2: Recursion's Position - Recursion Pharmaceuticals utilizes AI in its drug discovery process and has developed the largest supercomputer in the biopharmaceutical industry with Nvidia's assistance [3]. - Despite the positive sentiment, Recursion's experimental drugs are still in early testing stages, making it a riskier investment for conservative investors [5].

The most recent trading session ended with Recursion Pharmaceuticals (RXRX) standing at $8.50, reflecting a +1.92% shift from the previouse trading day's closing. The stock outperformed the S&P 500, which registered a daily gain of 1.04%. Meanwhile, the Dow experienced a rise of 0.77%, and the technology-dominated Nasdaq saw an increase of 1.51%.The the stock of biotechnology company has risen by 29.91% in the past month, leading the Medical sector's gain of 3.72% and the S&P 500's gain of 3.92%.Investors w ...

Company Overview - Recursion Pharmaceuticals (RXRX) shares increased by 8.9% to $8.34 in the last trading session, with a notable trading volume, and have gained 21.2% over the past four weeks [1][2] - The company utilizes its proprietary AI-based drug discovery platform, Recursion OS, to develop innovative therapeutic candidates for oncology, rare diseases, and infectious diseases [2] Financial Performance - Recursion Pharmaceuticals is projected to report a quarterly loss of $0.36 per share, reflecting a year-over-year increase of 10%, while revenues are expected to reach $28.73 million, a significant rise of 163.9% compared to the same quarter last year [3] - The consensus EPS estimate for Recursion has remained stable over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Recursion Pharmaceuticals is categorized under the Zacks Medical - Drugs industry, where another company, Bioventus (BVS), experienced a 3.8% decline to $10.27, despite a 20.4% return over the past month [4] - Bioventus has an unchanged consensus EPS estimate of $0.09 for its upcoming report, which represents a 28.6% increase from the previous year, and currently holds a Zacks Rank of 4 (Sell) [5]

Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse eventsIn comparison to placebo, treatment with REC-994 400 mg showed promising signals in both MRI-based lesion volume reduction and functional outcome as measured by changes in the modified Rankin scale (mRS) scoreIn patients with cavernomas located in the brainstem, a subset of patients with significant unmet need, decreases in mean absolute total lesion volume and improvements in ...

Recursion Pharmaceuticals (RXRX) shares ended the last trading session 8.9% higher at $7.49. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 5% loss over the past four weeks.The sudden rise in the stock price was observed after President Donald Trump announced a $500 billion project to develop and expand AI infrastructure, at his inauguration event on Monday. Investors likely anticipate that Recursion, being a Tech ...

AI in Healthcare Market Growth - The Generative AI in Healthcare Market is projected to reach US$17.2 billion by 2032, growing at a CAGR of 37% [2] - The Smart Healthcare Market, including telemedicine, mHealth, smart pills, and AI, is expected to grow by US$125.7 billion through 2028 [2] Avant Technologies and Ainnova Partnership - Avant Technologies and Ainnova have secured an exclusive license for 4 advanced AI algorithms for early detection of cardiovascular risk, prediabetes and type 2 diabetes, fatty liver disease, and chronic kidney disease [3][4] - These algorithms, validated with data from over 2 million patients, will be integrated into Ainnova's VisionAI platform [3][4] - The partnership aims to introduce these solutions in Latin America and secure FDA clearance for the U.S. market by 2025 [5][6] Industry Developments - Recursion Pharmaceuticals reported positive initial data from a Phase 1/2 study of REC-617, a CDK7 inhibitor, showing durable partial responses in advanced solid tumors [9][10] - Teladoc Health launched AI-enabled Virtual Sitter capabilities, increasing inpatient team capacity by 25% [10][11] - Butterfly Network partnered with HeartFocus to launch an AI-powered education app for cardiac care training [11][12] - Absci Corporation announced progress in its AI-driven drug creation pipeline, including potential treatments for hair loss and other conditions [12][13] Healthcare Professionals' Perspective - 90% of healthcare professionals report a favorable view of AI, highlighting its potential to transform clinical trials and healthcare delivery [1]